TapewireFind a company

person · Reporting owner

Riggsbee Richard Bryan

Disclosed activity across 3 companies

Tapewire entity
23555
SEC CIK
0001621899

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CareDx, Inc.CDNA · Entity 4344DirectorJune 12, 2026June 16, 2026
NEOGEN CORPNEOG · Entity 4338CFOAugust 14, 2026August 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CareDx, Inc.

Report date June 12, 2026 · Filed June 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect39,312 Reported balance After 2026-06-12 transaction · row 1
1 source row

Row 1 · 2026-06-12 · Grant · Acquired 9,795 · Balance 39,312

F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.

NEOGEN CORP

Report date August 14, 2026 · Filed August 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect51,502 Reported balance After 2026-08-14 transaction · row 1
1 source row

Row 1 · 2026-08-14 · Grant · Acquired 51,502 · Balance 51,502

F2: PSUs vest in total at the end of the three year anniversary date of the grant

Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2036-08-14Direct261,702 Reported balance After 2026-08-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-08-14 · Grant · Acquired 261,702 · Balance 261,702

F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants

Filing footnotes · ownership attribution and instrument terms

F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants

F2: PSUs vest in total at the end of the three year anniversary date of the grant

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MYRIAD GENETICS INC

Report date January 29, 2024 · Filed January 31, 2024

Section 16 reporting ended · disclosed 2024-01-31. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect291,812 Reported balance Holding disclosure · report date 2024-01-29 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 291,812

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 14, 2026 Filed Aug 15, 2026 00:53 UTC NEOGEN CORP NEOG · Entity 4338 GrantCommon Stock (Right to Buy) · Derivative 261,702 $0.00 Strike: $11.65 $0.00
Disclosure

SEC source: 0000711377-26-000015 · primary_doc.xml · derivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,702

Underlying: Common Stock · 261,702 shares

Expires 2036-08-14

F1 · derivative.exercise_date: Options vest in equal annual installments on each of the first three anniversary dates of the grants

Read SEC document
August 14, 2026 Filed Aug 15, 2026 00:53 UTC NEOGEN CORP NEOG · Entity 4338 GrantCommon Stock 51,502 $11.65 $599,998.30
Disclosure

SEC source: 0000711377-26-000015 · primary_doc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,502

F2 · shares: PSUs vest in total at the end of the three year anniversary date of the grant

Read SEC document
June 12, 2026 Filed Jun 16, 2026 21:50 UTC CareDx, Inc. CDNA · Entity 4344 GrantCommon Stock 9,795 $0.00 $0.00
Disclosure

SEC source: 0001621899-26-000001 · form4-06162026_090617.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,312

F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.

Read SEC document
November 03, 2025 Filed Nov 5, 2025 14:20 UTC NEOGEN CORP NEOG · Entity 4338 GrantCommon Stock (Right to Buy) · Derivative 459,713 $0.00 Strike: $6.29 $0.00
Disclosure

SEC source: 0000711377-25-000074 · primary_doc.xml · derivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 459,713

Underlying: Common Stock · 459,713 shares

Expires 2025-11-03

F1 · derivative.exercise_date: Options vest in equal annual installments on each of the first three anniversary dates of the grants

Read SEC document
November 03, 2025 Filed Nov 5, 2025 14:20 UTC NEOGEN CORP NEOG · Entity 4338 GrantCommon Stock 178,855 $6.29 $1,124,997.95
Disclosure

SEC source: 0000711377-25-000074 · primary_doc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,855

F2 · shares: PSUs vest in total at the end of the three year anniversary date of the grant

Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:30 UTC CareDx, Inc. CDNA · Entity 4344 GrantCommon Stock 12,103 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-087415 · ownership.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,517

F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on the earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Read SEC document
June 14, 2024 Filed Jun 17, 2024 23:06 UTC CareDx, Inc. CDNA · Entity 4344 GrantStock Option (right to buy) · Derivative 16,048 $0.00 Strike: $9.35 $0.00
Disclosure

SEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · derivative · entry 4

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,048

Underlying: Common Stock · 16,048 shares

Expires 2034-06-14

F4 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025.

Read SEC document
June 14, 2024 Filed Jun 17, 2024 23:06 UTC CareDx, Inc. CDNA · Entity 4344 GrantCommon Stock 10,570 $0.00 $0.00
Disclosure

SEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,414

F2 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025.

Read SEC document
June 14, 2024 Filed Jun 20, 2024 20:40 UTC Amendment CareDx, Inc. CDNA · Entity 4344 GrantStock Option (right to buy) · Derivative 16,048 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0000950170-24-075649 · ownership.xml · derivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,048

Underlying: Common Stock · 16,048 shares

Expires 2034-06-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4.

F3 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 23:06 UTC CareDx, Inc. CDNA · Entity 4344 GrantStock Option (right to buy) · Derivative 9,760 $0.00 Strike: $10.25 $0.00
Disclosure

SEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · derivative · entry 3

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,760

Underlying: Common Stock · 9,760 shares

Expires 2034-06-13

F3 · derivative.exercise_date: 1/36th of the shares subject to this option shall vest on April 11, 2024 and 1/36th of the shares subject to the option shall vest monthly thereafter through March 11, 2027.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 23:06 UTC CareDx, Inc. CDNA · Entity 4344 GrantCommon Stock 6,844 $0.00 $0.00
Disclosure

SEC source: 0001621899-24-000005 · wk-form4_1718665585.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,844

F1 · shares: The reported securities are represented by restricted stock units which shall vest in three equal annual installments beginning on March 11, 2025.

Read SEC document
June 13, 2024 Filed Jun 20, 2024 20:40 UTC Amendment CareDx, Inc. CDNA · Entity 4344 GrantStock Option (right to buy) · Derivative 9,760 $0.00 Strike: $14.61 $0.00
Disclosure

SEC source: 0000950170-24-075649 · ownership.xml · derivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,760

Underlying: Common Stock · 9,760 shares

Expires 2034-06-13

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4.

F2 · derivative.exercise_date: 1/36th of the shares subject to this option shall vest on April 11, 2024 and 1/36th of the shares subject to the option shall vest monthly thereafter through March 11, 2027.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:19 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 30,000 $19.09 $572,835.00
Disclosure

SEC source: 0001621899-23-000014 · wk-form4_1701811156.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 291,812

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.62 to $19.27, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 21:12 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 30,000 $15.69 $470,622.00
Disclosure

SEC source: 0001621899-23-000012 · wk-form4_1699045936.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 321,812

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $16.04, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 09, 2023 Filed Oct 10, 2023 20:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 7,382 $15.01 $110,803.82
Disclosure

SEC source: 0001621899-23-000010 · wk-form4_1696969324.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,812

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023.

Read SEC document
October 09, 2023 Filed Oct 10, 2023 20:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,954 $15.01 $74,359.54
Disclosure

SEC source: 0001621899-23-000010 · wk-form4_1696969324.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,194

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023.

Read SEC document
September 26, 2023 Filed Sep 27, 2023 20:32 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,517 $15.99 $72,226.83
Disclosure

SEC source: 0001621899-23-000008 · wk-form4_1695846764.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 364,148

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2023.

Read SEC document
March 24, 2023 Filed Mar 27, 2023 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,307 $23.72 $125,882.04
Disclosure

SEC source: 0001628280-23-009259 · wf-form4_167994883346896.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,665

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023.

Read SEC document
March 24, 2023 Filed Mar 27, 2023 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,622 $23.72 $85,913.84
Disclosure

SEC source: 0001628280-23-009259 · wf-form4_167994883346896.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,972

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023.

Read SEC document
March 22, 2023 Filed Mar 23, 2023 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,074 $22.91 $93,335.34
Disclosure

SEC source: 0001628280-23-009045 · wf-form4_167960326581990.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,594

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023.

Read SEC document
March 15, 2023 Filed Mar 16, 2023 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 43,783 $0.00 $0.00
Disclosure

SEC source: 0001628280-23-008323 · wf-form4_167899868751482.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,668

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
March 02, 2023 Filed Mar 3, 2023 22:07 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 15,000 $22.55 $338,253.00
Disclosure

SEC source: 0001621899-23-000005 · wf-form4_167788121229192.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,885

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 18, 2023 Filed Feb 21, 2023 21:34 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 11,222 $19.42 $217,931.24
Disclosure

SEC source: 0001621899-23-000003 · wf-form4_167701522597948.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,885

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 17, 2023.

Read SEC document
January 20, 2023 Filed Jan 23, 2023 21:14 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 9,400 $20.04 $188,386.34
Disclosure

SEC source: 0001621899-23-000002 · wf-form4_167450842679054.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,107

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.12, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 18, 2023 Filed Jan 19, 2023 22:56 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 600 $20.01 $12,006.00
Disclosure

SEC source: 0001621899-23-000001 · wf-form4_167416896780055.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 373,507

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 27, 2022 Filed Dec 28, 2022 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 20,000 $15.15 $302,992.00
Disclosure

SEC source: 0001621899-22-000008 · wf-form4_167226151057587.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 374,107

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.54, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 09, 2022 Filed Oct 11, 2022 20:35 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 7,411 $19.62 $145,403.82
Disclosure

SEC source: 0001628280-22-026253 · wf-form4_166552053717645.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,107

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022.

Read SEC document
October 09, 2022 Filed Oct 11, 2022 20:35 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,974 $19.62 $97,589.88
Disclosure

SEC source: 0001628280-22-026253 · wf-form4_166552053717645.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,518

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022.

Read SEC document
September 26, 2022 Filed Sep 27, 2022 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,543 $18.41 $83,636.63
Disclosure

SEC source: 0001628280-22-025563 · wf-form4_166431065748425.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,492

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022.

Read SEC document
September 25, 2022 Filed Sep 27, 2022 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,263 $18.69 $98,365.47
Disclosure

SEC source: 0001628280-22-025563 · wf-form4_166431065748425.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,035

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022.

Read SEC document
August 25, 2022 Filed Aug 26, 2022 20:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,056 $24.89 $76,063.84
Disclosure

SEC source: 0001628280-22-023767 · wf-form4_166154532207583.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 416,298

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022.

Read SEC document
August 15, 2022 Filed Aug 26, 2022 20:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GiftCommon Stock 2,150 $0.00 $0.00
Disclosure

SEC source: 0001628280-22-023767 · wf-form4_166154532207583.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 419,354

Read SEC document
March 24, 2022 Filed Mar 25, 2022 21:00 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,323 $25.32 $134,778.36
Disclosure

SEC source: 0001621899-22-000006 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,504

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022.

Read SEC document
March 24, 2022 Filed Mar 25, 2022 21:00 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,633 $25.32 $91,987.56
Disclosure

SEC source: 0001621899-22-000006 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 426,827

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022.

Read SEC document
March 22, 2022 Filed Mar 23, 2022 20:50 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 36,866 $0.00 $0.00
Disclosure

SEC source: 0001621899-22-000004 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,460

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 18, 2022 Filed Feb 18, 2022 22:39 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 11,180 $25.69 $287,214.20
Disclosure

SEC source: 0001621899-22-000002 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,594

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 18, 2022.

Read SEC document
February 16, 2022 Filed Feb 18, 2022 22:39 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 48,009 $0.00 $0.00
Disclosure

SEC source: 0001621899-22-000002 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 404,774

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025.

Read SEC document
October 09, 2021 Filed Oct 12, 2021 20:52 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 7,419 $30.88 $229,098.72
Disclosure

SEC source: 0001621899-21-000013 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,765

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021.

Read SEC document
October 09, 2021 Filed Oct 12, 2021 20:52 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,979 $30.88 $153,751.52
Disclosure

SEC source: 0001621899-21-000013 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,184

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021.

Read SEC document
September 26, 2021 Filed Sep 27, 2021 23:33 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,541 $33.31 $151,260.71
Disclosure

SEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,163

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

Read SEC document
September 25, 2021 Filed Sep 27, 2021 23:33 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 11,907 $33.31 $396,622.17
Disclosure

SEC source: 0001621899-21-000011 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 373,704

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.

Read SEC document
September 21, 2021 Filed Sep 23, 2021 21:17 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 66,977 $0.00 $0.00
Disclosure

SEC source: 0001621899-21-000009 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,611

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

Read SEC document
August 25, 2021 Filed Aug 27, 2021 01:53 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,058 $34.81 $106,448.98
Disclosure

SEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 2

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,634

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021.

Read SEC document
August 10, 2021 Filed Aug 27, 2021 01:53 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GiftCommon Stock 3,250 $0.00 $0.00
Disclosure

SEC source: 0001621899-21-000007 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,692

Read SEC document
August 03, 2021 Filed Aug 5, 2021 21:23 UTC MYRIAD GENETICS INC MYGN · Entity 5953 SaleCommon Stock 14,983 $35.14 $526,475.65
Disclosure

SEC source: 0001621899-21-000006 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,942

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 24, 2021 Filed Mar 26, 2021 20:15 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 32,774 $0.00 $0.00
Disclosure

SEC source: 0001621899-21-000004 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,925

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 18, 2021 Filed Feb 22, 2021 21:46 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Disposition to issuerCommon Stock 11,175 $29.69 $331,785.75
Disclosure

SEC source: 0001621899-21-000002 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,151

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person.

Read SEC document
October 08, 2020 Filed Oct 13, 2020 12:02 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 44,954 $0.00 $0.00
Disclosure

SEC source: 0001621899-20-000012 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,326

F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

Read SEC document
September 30, 2020 Filed Oct 1, 2020 21:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Disposition to issuerCommon Stock 6,653 $13.04 $86,755.12
Disclosure

SEC source: 0001621899-20-000010 · edgardoc.xml · nonDerivative · entry 1

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,372

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person.

Read SEC document
September 26, 2020 Filed Sep 28, 2020 16:42 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Disposition to issuerCommon Stock 4,546 $12.44 $56,552.24
Disclosure

SEC source: 0001621899-20-000008 · edgardoc.xml · nonDerivative · entry 4

Riggsbee Richard Bryan · CIK 0001621899 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,025

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.